had voluntarily recalled select batches of its Irbesartan Tablets and Irbesartan and Hydrochlorothiazide Tablets USP, medications commonly used to control high blood pressure.

Irbesartan Tablets USP with NDC numbers 68180-411-06 and 68180-411-09, and 300-mg.

Irbesartan Tablets USP with NDC numbers 68180-412-06 and 68180-412-09, all of which were distributed on Oct.

Irbesartan and Hydrochlorothiazide Tablets USP with NDC numbers 68180-413-06 and 68180-413-09 and 300-mg./12.5-mg.

Irbesartan and Hydrochlorothiazide Tablets USP with NDC numbers 68180-414-06 and 68180-414-09, both of which were distributed on Oct!

The recall was initiated after it was discovered that the medications may have levels of N-nitroso irbesartan that exceed acceptable limits for human consumption.

"N-nitroso irbesartan impurity is a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests," the recall notice explains.

30, 2021, Lupin Pharmaceuticals received four reports of individuals becoming ill after taking Irbesartan and no reported illnesses associated with Irbesartan and Hydrochlorothiazide.

Despite the potential impurity, individuals prescribed the recalled medications are advised to continue taking them until a healthcare professional can implement an alternate treatment plan.

RELATED: If You Use Any of These OTC Medications, Throw Them Out Now, Maker Says.